Evaluation of Thoracic Aortic Aneurysm Mortality with Low-Dose Computed Tomographic Screening.
The US Preventive Services Task Force recommends one-time ultrasound screening for abdominal aortic aneurysm (AAA) in males age 65-74 years old who have ever smoked. Similar one-time screening recommendations are in practice in the United Kingdom and Sweden. A single ultrasound screening for AAA has been shown to half the mortality rate due to AAA in men aged 65-74 years. However, nearly half of deaths from ruptured abdominal aneurysms in the United States occur in patients outside these limited screening criteria. Additionally, screening has not been extended to thoracic aortic disease.
Established risk factors for TAA include male sex, prior and active smoking, hypertension, emphysema, and familial history. Lung cancer and TAA share many of these same risk factors and can both be detected on a chest X-ray or non-contrast, low-dose CT scan. Through analysis of existing imaging studies, we hope to define the incidence of thoracic aortic disease among lung cancer screening patients, those aged 55-75 years, with at least 30 pack year smoking history and who actively smoke or have quit within the past 15 years. Clinical data available in the National Lung Cancer Screening (NCLS) trial includes many variables relevant to this study, including significant cardiovascular abnormalities found on imaging, participant demographics and risk factors, long-term mortality and cause of death, as well as non-cancer ICD-10 diagnosis codes. Our primary outcomes will be thoracic aortic disease detected on lung cancer screening imaging and cardiovascular mortality among those with and without detected aortic disease.
Our research group includes 3 aortic surgeons, a cardiovascular radiologist, statistician and research information technologist. We have the resources and institutional support to perform an analysis similar to that done by the NLCS Trial research team. A positive result in this data may justify a larger screening trial targeted at thoracic aortic disease, while a negative result will offer further insight to the topic. The ability to identify a thoracic aortic disease prior to aortic catastrophe would not only prevent aortic-related mortality but would decrease complications and improve the quality of life for aortic patients. The NLCS trial was a monumental improvement in the care of lung cancer patients. We hope to use this data to similarly advance the care of aortic patients.
1. To determine the incidence of thoracic aortic disease among patients aged 55-75, with at least a 30 pack year smoking history, who are actively smoking or have quit within 15 years, that can be identified on:
A: Chest X-Ray
B: Low-Dose Computed Tomography
2. To determine the incidence of aortic-related deaths among patients aged 55-75, with at least a 30 pack year smoking history, who are actively smoking or have quit within 15 years, with disease identified on screening imaging.
1. A. Claire Watkins, MD, MS. Department of Cardiothoracic Surgery. Stanford University.
2. Dominick Fleischmann, MD. Chief, Cardiovascular Imaging. Department of Radiology. Stanford University.
3. Jason T Lee, MD. Director of Endovascular Surgery. Division of Vascular Surgery. Stanford University.
4. Michael P Fischbein, MD, PhD. Department of Cardiothoracic Surgery. Stanford University.
5. Bharathi Lingala, PhD. Department of Cardiothoracic Surgery. Stanford University.
6. Eileen Lol, MS. Research Information Technology. Stanford University.